Hepatic progenitor cells in human liver tumor development

World Journal of Gastroenterology

Volumn 12, Issue 39, 2006, Pages 6261-6265

  Libbrecht, Louis ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Hepatic progenitor cell; Hepatocellular carcinoma; Liver tumor

Indexed keywords

CELL MARKER;

BILE DUCT CARCINOMA; CELL DIFFERENTIATION; CELL MATURATION; CELL TYPE; EDITORIAL; HUMAN; HUMAN CELL; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; PROGNOSIS; STEM CELL;

EID: 33750798339     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i39.6261     Document Type: Editorial

References (45)

1. Libbrecht L, Roskams T. Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol 2002; 13: 389-396
2. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999; 154: 537-541
3. Libbrecht L, Desmet V, Van Damme B, Roskams T. Deep intralobular extension of human hepatic 'progenitor cells' correlates with parenchymal inflammation in chronic viral hepatitis: can 'progenitor cells' migrate? J Pathol 2000; 192: 373-378
4. Eleazar JA, Memeo L, Jhang JS, Mansukhani MM, Chin S, Park SM, Lefkowitch JH, Bhagat G. Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis. J Hepatol 2004; 41: 983-991
5. Alison MR, Lovell MJ. Liver cancer: the role of stem cells. Cell Prolif 2005; 38: 407-421
6. Tan J, Hytiroglou P, Wieczorek R, Park YN, Thung SN, Arias B, Theise ND. Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver 2002; 22:365-373
7. Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002; 23: 435-445
8. Braun L, Mikumo R, Fausto N. Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res 1989; 49: 1554-1561
9. Bralet MP, Pichard V, Ferry N. Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology 2002; 36: 623-630
10. Lin YZ, Brunt EM, Bowling W, Hafenrichter DG, Kennedy SC, Flye MW, Ponder KP. Ras-transduced diethylnitrosamine-treated hepatocytes develop into cancers of mixed phenotype in vivo. Cancer Res 1995; 55: 5242-5250
11. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-416
12. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005; 25: 16-27
13. Hsia CC, Thorgeirsson SS, Tabor E. Expression of hepatitis B surface and core antigens and transfoming growth factor-alpha in "oval cells" of the liver in patients with hepatocellular carcinoma. J Med Virol 1994; 43: 216-221
14. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams, T. The clinico-pathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-151
15. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94: 851-857
16. Yoon DS, Jeong J, Park YN, Kim KS, Kwon SW, Chi HS, Park C, Kim BR. Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. Yonsei Med J 1999; 40: 472-477
17. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996; 149: 1167-1175
18. Van Eyken P, Sciot R, Paterson A, Callea F, Kew MC, Desmet VJ. cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1988; 19: 562-568
19. Sell S. Cellular origin of cancer: dedifferentiation or stem cell maturation arrest? Environ Health Perspect 1993; 101 Suppl 5: 15-26
20. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao, XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004; 3: 73-81
21. Libbrecht L, Desmet V, Van Damme B, Roskams T. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000; 33: 76-84
22. Libbrecht L, De Vos R, Cassiman D, Desmet V, Aerts R, Roskams T. Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Pathol 2001; 25: 1388-1396
23. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432: 324-331
24. Xiao JC, Ruck P, Kaiserling E. Small epithelial cells and the histogenesis of hepatocellular carcinoma. Morphological, immunohistochemical and electron miroscopical findings. Pathol Res Pract 1996; 192: 343
25. Fiorentino M, Altimari A, Ravaioli M, Gruppioni E, Gabusi E, Corti B, Vivarelli M, Bringuier PP, Scoazec JY, Grigioni WF, D'Errico-Grigioni A. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 2004; 10: 1789-1795
26. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G, Benedetti E, Kajdacsy-Balla A, Coder SJ. p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 2005; 18: 1498-1503
27. Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Monden M. Both cell prolfferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 747-751
28. Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 2003; 200: 553-560
29. Bisgaard HC, Holmskov U, Santoni-Rugiu E, Nagy P, Nielsen O, Ott P, Hage E, Dalhoff K, Rasmussen LJ, Tygstrup N. Heterogeneity of ductular reactions in adult rat and human liver revealed by novel expression of deleted in malignant brain tumor 1. Am J Pathol 2002; 161: 1187-1198
30. Chang JC, Hilsenbeck SG, Fuqua SA. Genomic approaches in the management and treatment of breast cancer. Br J Cancer 2005; 92: 618-624
31. Haratake J, Hashimoto H. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma. Liver 1995; 15: 9-15
32. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985; 55: 124-135
33. Tickoo SK, Zee SY, Obiekwe S, Xiao H, Koea. J, Robiou C, Blumgart LH, Jarnagin W, Ladanyi M, Klimstra DS. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol 2002; 26: 989-997
34. Wittekind C, Fisher HP, Ponchon T. Combined hepatocellular and cholangiocarcinoma. In: World Health Organization classification of tumors: pathology and genetics of tumors of the digestive system. Lyon: IARC Press, 2000: 181
35. Aishima S, Kuroda Y, Asayama Y, Taguchi K, Nishihara Y, Taketomi A, Tsuneyoshi M. Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Hum Pathol 2006; 37: 283-291
36. Tanaka S, Yamamoto T, Tanaka H, Kodai S, Ogawa M, Ichikawa T, Hai S, Sakabe K, Uenishi T, Shuto T, Kubo S. Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell: Immunohistochemical evidence. Hepatol Res 2005; 32: 52-57
37. Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, Park YN. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004; 40: 298-304
38. Robrechts C, De Vos R, Van den Heuvel M, Van Cutsem E, Van Damme B, Desmet V, Roskams T. Primary liver tumour of intermediate (hepatocyte bile duct cell) phenotype: a progenitor cell tumour? Liver 1998; 18: 288-293
39. Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, Rhee JC, Cho JW, Park CK, Kim HJ. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 2005; 189: 120-125
40. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada. K, Ojima H, Sakamoto, M, Takayama T, Makuuchi M. Combined hepatocellular and cholangiocarcinoma: a clinico-pathologic study of 26 resected cases. Jpn J Clin Oncol 2003; 33: 283-287
41. Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, Blumgart LH, Klimstra D. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002; 94: 2040-2046
42. Ng IO, Shek TW, Nicholls J, Ma LT. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol 1998; 13: 34-40
43. Lee JH, Rim HJ, Sell S. Heterogeneity of the "oval-cell" response in the hamster liver during cholangiocarcinogenesis following Clonorchis sinensis infection and dimethylnitrosamine treatment. J Hepatol 1997; 26: 1313-1323
44. Steinberg P, Steinbrecher R, Radaeva S, Schirmacher P, Dienes HP, Oesch F, Bannasch P. Oval cell lines OC/CDE 6 and OC/CDE 22 give rise to cholangiocellular and undifferentiated carcinomas after transformation. Lab Invest 1994; 71: 700-709
45. Asayama Y, Aishima S, Taguchi K, Sugimachi K, Matsuura S, Masuda K, Tsuneyoshi M. Coexpression of neural cell adhesion molecules and bcl-2 in intrahepatic cholangiocarcinoma originated from viral hepatitis: relationship to atypical reactive bile ductule. Pathol Int 2002; 52:300-306